Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Stern, Anat ^a   Green, Hefziba ^b   Paul, Mical ^a   Vidal, Liat ^b   Leibovici, Leonard ^b  

^a Division of Infectious Diseases   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; OFLOXACIN; PLACEBO; PYRIMETHAMINE PLUS SULFADOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ALL CAUSE MORTALITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BACTERIAL INFECTION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; HEART TRANSPLANTATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TRANSPLANTATION; MULTIPLE MYELOMA; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; ADULT; CHILD; META ANALYSIS; PNEUMONIA, PNEUMOCYSTIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SERODIAGNOSIS;

ADULT; ANTI-INFECTIVE AGENTS; CHILD; HIV SERONEGATIVITY; HUMANS; IMMUNOCOMPROMISED HOST; PNEUMONIA, PNEUMOCYSTIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84921979180     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005590.pub3     Document Type: Review

References (92)

1. Arning M, Wolf HH, Aul C, Heyll A, Scharf RE, Scheider W. Infection prophylaxis in neutropenic patients with acute leukaemia--a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin. Journal of Antimicrobial Chemotherapy 1990;26 Suppl D:137-42.
2. Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 1999;24(8):897-902.
3. Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. American Journal of Medicine 1990;89(3):255-74.
4. Maki DG, Fox BC, Kuntz J, Sollonger HW, Belzer OB. A prospective, randomised, double-blind study of thrimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim-sulfamethoxazole, interaction with cyclosporine. The Journal of Laboratory and Clinical Medicine 1992;119(1):11-24.
5. Goorin AM, Hershey BJ, Levin MJ, Siber GR, Gelber RD, Flynn K, et al.Use of trimethoprim-sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatric Infectious Disease 1985;4(3):265-9.
6. Hibberd PL, Tolkoff-Rubin NE, Doran M, Delvecchio A, Cosimi AB, Delmonico FL, et al.Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double-blind, randomized controlled trial. Online Journal of Current Clinical Trials 1992; Vol. Doc No 15.
7. Hughes WT, Kuhn S, Chaudhary S, Feldman S, Verzosa M, Aur RJ, et al.Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine 1977;297(26):1419-26.
8. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. The New England Journal of Medicine 1987;316(26):1627-32.
9. Liang RH, Yung RW, Chan TK, Chau PY, Lam WK, So SY, et al.Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrobial Agents and Chemotherapy 1990;34(2):215-8.
10. Olsen SL, Renlund DG, O'Connell JB, Taylor DO, Lassetter JE, Eastburn TE, et al.Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation 1993;56(2):359-62.
11. Torre-Cisneros J, De la Mata M, Pozo JC, Serrano P, Briceno J, Solorzano G, et al.Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clinical Infectious Disease 1999;29(4):771-4.
12. van Eys J, Berry DM, Crist W, Doering EJ, Fernbach DJ, Pullen J, et al.Effect of trimethoprim/sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. A Pediatric Oncology Group Study. Cancer 1987;59(1):19-23.
13. Vesole DH, Oken MM, Heckler C, Greipp PR, Katz MS, Jacobus S, Morrow GR, on behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group. Oral antibiotic prophylaxis of early infection in multiple myeloma:a URCC/ECOG randomized phase III study. Leukemia 2012;26:2517-20.
14. Ward TT, Thomas RG, Fye CL, Arbeit R, Coltman CA Jr, Craig W, et al.Trimethoprim-sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double-blind, placebo-controlled Department of Veterans Affairs Cooperative Study. Clinical Infectious Diseases 1993;17(3):323-32.
15. Arend SM, Westendorp RG, Kroon FP, van't Wout JW, Vandenbroucke JP, van Es LA, et al.Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clinical Infectious Disease 1996;22(6):920-5.
16. Arico M, Molinari E, Bacchella L, DeAmici M, Raiteri E, Burgio GR. Prospective randomized comparison of toxicity of two prophylactic regimens of cotrimoxazole in leukemic children. Pediatric Hematology and Oncology 1992;9(1):35-40.
17. Carlin EM, Coker RJ, Goldin RD, Harris JR. Systemic Pneumocystis carinii pneumonia prophylaxis with dapsone and pyrimethamine fails to protect against extrapulmonary pneumocystosis. Genitourinary Medicine 1993;69(2):130-2.
18. Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Arthritis and Rheumatism 2000;43(8):1841-8.
19. Coker RJ, Nieman R, McBride M, Mitchell DM, Harris JR, Weber JN. Co-trimoxazole versus dapsone-pyrimethamine for prevention of Pneumocystis carinii pneumonia. Lancet 1992;340(8827):1099.
20. de Jongh CA, Wade JC, Finley RS, Joshi JH, Aisner J, Wiernik PH, Schimpff SC. Trimethoprim/sulfamethoxazole versus placebo: a double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung. Journal of Clinical Oncology 1983;1(5):302-7.
21. Elinder CG, Andersson J, Bolinder G, Tyden G. Effectiveness of low-dose cotrimoxazole prophylaxis against Pneumocystis carinii pneumonia after renal and/or pancreas transplantation. Transplant International 1992;5(2):81-4.
22. Golden JA, Katz MH, Chernoff DN, Duncan SM, Conte JE Jr. A randomized comparison of once-monthly or twice-monthly high-dose aerosolized pentamidine prophylaxis. Chest 1993;104(3):743-50.
23. Groll AH, Ritter J, Muller FM. [Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer]. Klinische Pediatrie 2001;213 Suppl 1:A38-49.
24. Holt CD, Ingle G, Kunder G, Ghobrial RM, Busutti RW. Aerosolized pentamidine (APNT) compared to trimethoprim/sulfamethoxazole (TMP/SMX) for pneumocystis carinii pneumonia prophylaxis (PCP) following orthotopic liver transplantation. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2000.
25. Janner D, Bork J, Baum M, Chinnock R. Pneumocystis carinii pneumonia in infants after heart transplantation. Journal of Heart and Lung Transplantation 1996;15(8):758-63.
26. Kramer BS, Carr DJ, Rand KH, Pizzo PA, Johnson A, Robichaud KJ, et al.Prophylaxis of fever and infection in adult cancer patients. A placebo-controlled trial of oral trimethoprim-sulfamethoxazole plus erythromycin. Cancer 1984;53(2):329-35.
27. Kramer MR, Stoehr C, Lewiston NJ, Starnes VA, Theodore J. Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation--how effective and for how long?. Transplantation 1992;53(3):586-9.
28. Mallolas J, Zamora L, Gatell JM, Miro JM, Soriano E. Low-dose co-trimoxazole, aerosolised pentamidine, or dapsone plus pyrimethamine for prevention of Pneumocystis carinii pneumonia. Lancet 1991;337(8750):1162-3.
29. Maschmeyer G, Daenen S, de Pauw BE, de Vries-Hospers HG, Dekker AW, Donnelly JP, et al.Prevention of infection in acute leukemia. Haematology and Blood Transfusion 1990;33:525-30.
30. Mehta J, Powles R, Singhal S, Riley U, Treleaven J, Catovsky D. Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic lymphocytic leukemia after allogeneic blood or marrow transplantation. Leukemia and Lymphoma 1997;26(1-2):83-8.
31. Meyers B, Borrego F, Papanicolaou G. Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study. Liver Transplantation 2001;7(8):750-1.
32. Moriuchi Y, Kamihira S, Satoh T, Yanagisako T, Miyazaki Y, Nagai K, et al.[Infection prophylaxis in patients with hematological malignancies (I)--successful prophylaxis of Pneumocystis carinii pneumonitis with sulfamethoxazole-trimethoprim]. Rinsho Ketsueki 1990;31(11):1818-22.
33. Mustafa MM, Pappo A, Cash J, Winick NJ, Buchanan GR. Aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in children with cancer intolerant or allergic to trimethoprim/sulfamethoxazole. Journal of Clinical Oncology 1994;12(2):258-61.
34. Nucci M, Andrade F, Vigorito A, Trabasso P, Aranha JF, Maiolino A. Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. Transplant Infectious Disease 2003;5(4):167-73.
35. Okada J, Kadoya A, Rana M, Ishikawa A, Iikuni Y, Kondo H. Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease. Kansenshogaku Zasshi 1999;73(11):1123-9.
36. Oken MM, Pomeroy C, Weisdorf D, Bennett JM. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. American Journal of Medicine 1996;100(6):624-8.
37. Pedagogos E, Nicholls K, Wilson J, Waiker R, Becker G. Comparison of oral trimethoprim/sulfamethoxazole (TMP-SMX) and inhaled pentamidine (P) for prevention of pneumocystis pneumonia (PCP) after renal transplantation. The Transplantation Society of Australia and New Zealand 1994.
38. Rossi MR, Banfi P, Cappuccilli M, Conter V, de Poli D, Piacentini G, et al.Prospective randomized comparison of two prophylactic regimens with trimethoprim-sulfamethoxazole in leukemic children: a two year study. European Journal of Cancer & Clinical Oncology 1987;23(11):1679-82.
39. Singer NG, McCune WJ. Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections. Current Opinion in Rheumatology 1999;11(3):173-8.
40. Slavin MA, Hoy JF, Stewart K, Pettinger MB, Lucas CR, Kent SJ. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS 1992;6(10):1169-74.
41. Souza JP, Boeckh M, Gooley TA, Flowers ME, Crawford SW. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clinical Infectious Diseases 1999;29(6):1467-71.
42. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. The New England Journal of Medicine 1996;335(1):16-20.
43. Torre-Cisneros J, de la Mata M, Lopez-Cillero P, Sanchez-Guijo P, Mino G, Pera C. Effectiveness of daily low-dose cotrimoxazole prophylaxis for Pneumocystis carinii pneumonia in liver transplantation--an open clinical trial. Transplantation 1996;62(10):1519-21.
44. Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biology of Blood and Marrow Transplantation 2000;6(1):35-43.
45. Weinthal J, Frost JD, Briones G, Cairo MS. Successful Pneumocystis carinii pneumonia prophylaxis using aerosolized pentamidine in children with acute leukemia. Journal of Clinical Oncology 1994;12(1):136-40.
46. Worth LJ, Dooley MJ, Seymour JF, Mileshkin L, Slavin MA, Thursky KA. An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. British Journal of Cancer 2005;92(5):867-72.
47. Young RC, DeVita VT Jr. Treatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine. National Cancer Institute Monograph 1976;43:193-200.
48. Young LS, Hindler J. Use of trimethoprim-sulfamethoxazole singly and in combination with other antibiotics in immunocompromised patients. Reviews of Infectious Diseases 1987;9 Suppl 2:S177-83.
49. The Safety and Effectiveness of Trimethoprim/Sulfamethoxazole as Pneumocystis Carinii Pneumonia (PCP) Prophylaxis in Patients With Connective Tissue Diseases. Ongoing study August 2012.
50. Bozzette SA, Forthal D, Sattler FR, Kemper C, Richman DD, Tilles JG, et al.The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group. American Journal of Medicine 1995;98:177-82.
51. Chapman JR, Marriott DJ, Chen SC, MacDonald PS. Post-transplant Pneumocystis jirovecii pneumonia--a re-emerged public health problem?. Kidney International 2013;84(2):240-3.
52. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, et al.CHAP trial team. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004;364(9448):1865-71.
53. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
54. De Castro N, Neuville S, Sarfati C, Ribaud P, Derouin F, Gluckman E, et al.Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplantation 2005;36(10):879-83.
55. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis and Rheumatism 2003;48:3013-22.
56. FDA . Safety update on TNF-alfa antagonists: infliximab and etanerecept. Food and Drug Administration, Center for Biologics Evaluation and Research. Arthritis Advisory Committee Meeting, 2001.
57. Gigliotti F, Wright TW. Pneumocystis: where does it live?. PLoS Pathogens 2012;8(11):e1003025.
58. Grimwade K, Swingler G. Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD003108]
59. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999;354(9187):1347-51.
60. Huang L, Crothers K, Atzori C, Benfield T, Miller R, Rabodonirina M, Helweg-Larsen J. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerging Infectious Diseases 2004;10(10):1721-8.
61. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al.KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney International 2010;77(4):299-311.
62. Kazanjian P, Armstrong W, Hossler PA, Burman W, Richardson J, Lee CH, et al.Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. Journal of Infectious Diseases 2000;182:551-7.
63. Long MD, Farraye FA, Okafor PN, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2013;19(5):1018-24.
64. Walzer PD, Smulian AG. Pneumocystis species. Mandel, Douglas and Bennet's principles and practice of infectious diseases. Vol. 2, Churchill Livingstone, 2010:3377-90.
65. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000;118:704-11.
66. Martin SI, Fishman JA, AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplantation. American Journal of Transplantation 2013;13 Suppl 4:272-9.
67. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al.Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004;364(9443):1428-34.
68. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
69. Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clinical Microbiology Reviews 2012;25(2):297-317.
70. Nankivell BJ, Firacative C, Kable K, Chen SC, Meyer W. Molecular epidemiology linking multihospital clusters of opportunistic Pneumocystis jirovecii pneumonia. Clinical Infectious Diseases 2013;57(7):1058-9.
71. Navin TR, Beard CB, Huang L, del Rio C, Lee S, Pieniazek NJ, et al.Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study. Lancet 2001;358:545-9.
72. Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology 2013;92(4):433-42.
73. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.
74. Ponce CA, Gallo M, Bustamante R, Vargas SL. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clinical Infectious Diseases 2010;50(3):347-53.
75. Rabodonirina M, Vaillant L, Taffe P, Nahimana A, Gillibert RP, Vanhems P, et al.Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia. Emerging Infectious Diseases 2013;19:21-8; quiz 186.
76. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, et al.European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn's & Colitis 2009;3(2):47-91.
77. Raychaudhuri SP, Siu S. Pneumocystis carinii pneumonia in patients receiving immunosuppressive drugs for dermatological diseases. British Journal of Dermatology 1999;141:528-30.
78. Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, et al.Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. European Journal of Clinical Microbiology & Infectious Diseases 2002;21(7):523-31.
79. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clinical Microbiology Reviews 2004;17:770-82.
80. Rostved AA, Sassi M, Kurtzhals JA, Sorensen SS, Rasmussen A, Ross C, et al.Outbreak of pneumocystis pneumonia in renal and liver transplant patients caused by genotypically distinct strains of Pneumocystis jirovecii. Transplantation 2013;96:834-42.
81. Roux A, Gonzalez F, Roux M, Mehrad M, Menotti J, Zahar JR, et al.Groupe de recherche respiratoire en réanimation en onco-hématologie (Grrr-OH). Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Médecine et Maladies Infectieuses 2014;44(5):185-98.
82. Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. Journal of Infectious Diseases 1994;170:912-7.
83. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
84. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clinical Infectious Diseases 1993;17 Suppl 2:S416-22.
85. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clinical Infectious Diseases 2002;34:1098-107.
86. Stein CR, Poole C, Kazanjian P, Meshnick SR. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerging Infectious Diseases 2004;10:1760-5.
87. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al.Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biology of Blood and Marrow Transplantation 2009;15(10):1143-238.
88. Vargas SL, Hughes WT, Santolaya ME, Ulloa AV, Ponce CA, Cabrera CE, et al.Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clinical Infectious Diseases 2001;32:855-61.
89. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clinics Proceedings 1996;71:5-13.
90. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation 2009;88:380-5.
91. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database of Systematic Reviews 2007, Issue 18(3). [DOI: 10.1002/14651858.CD005590.pub2]
92. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: Systematic review and meta-analysis of randomized controlled trials. Mayo Clinics Proeedings 2007;82(9):1052-9.